Pharmaceuticals

ZHAOKE OPHTH-B

ZHAOKE Ophthalmology-B expects multiple products to be approved in the second half of the year

ZHAOKE OPHTH-B released FY2025 9 Months Earnings on March 25, 2026 (BJT), actual revenue HKD 25.95 M, actual EPS HKD -0.3242

ZHAOKE OPHTH-B released FY2025 Q3 earnings on March 25 (BJT), actual revenue HKD 8.839 M, actual EPS HKD -0.0929

ZHAOKE OPHTH-B released FY2025 Q4 earnings on March 25 After-Market (BJT), actual revenue HKD 8.991 M, actual EPS HKD -0.0945

ZHAOKE OPHTH-B released FY2025 Annual Earnings on March 25 After-Market (BJT), Actual Revenue: HKD 34.95 M (Forecast: HKD 271.34 M), Actual EPS: HKD -0.4176 (Forecast: HKD -1.0045)

ZHAOKE OPHTH-B to Release FY2025 Earnings on March 25 After-Market (BJT), Forecast Revenue HKD 271.34 M, EPS HKD -1.0045

ZHAOGEOcular-B Receives Approval for PAN-90806 Ophthalmic Solution Clinical Trial Application

ZHAOKE Ophthalmology Signs Distribution Agreement with PT Ferron Par Pharmaceuticals for BRIMOCHOL™ PF

Zhaok 眼科's Core Drug Candidates Expected to be Approved for Market Entry Next Year

Zekewell Announces Interim Results, Anticipates Narrowing Losses, and Advances Multiple Product Development and Launch Plans

ZHAOKE OPHTH-B released FY2025 Q1 earnings on August 28 (BJT), actual revenue HKD 8.462 M, actual EPS HKD -0.1143

ZHAOKE Ophthalmology-B Reports Increased Loss in Mid-Year Earnings

ZHAOKE OPHTH-B released FY2025 Q2 earnings on August 28 During-Market BJT, actual revenue HKD 8.648 M, actual EPS HKD -0.1168

ZHAOKE OPHTH-B released FY2025 Semi-Annual Earnings on August 28 During-Market BJT, actual revenue HKD 17.11 M, actual EPS HKD -0.2312

ZHAOKE OPHTH-B to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Zhaok 眼科 Gains Orphan Drug Designation from US FDA

ZHAOKE Ophthalmology-B enters strategic partnership with FAREVA

ZKSEC Pharmaceuticals Partners with Somerset Therapeutics

ZKLB's NVK002 New Drug Application for Marketing Accepted

ZKEO Appoints New Nomination Committee Members

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

06622

Zhaoke Ophthalmology Ltd. announced that all resolutions at its 2026 AGM were approved by shareholders. This includes mandates for share repurchase and issuance, re-election of directors, and the re-appointment of KPMG as auditor. A special resolution to amend the company's memorandum and articles of association was also passed, indicating a focus on governance and strategic alignment.

Tip Ranks

Zhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGM

300015

02219

512010

China's leading private ophthalmology hospital chain Aier Eye plans to go public in Hong Kong to enhance brand awareness and broaden financing channels. Despite facing intense competition and price pressure, the company hopes to achieve growth through the expansion of the international ophthalmology market. Last year, its overseas ophthalmology clinic revenue grew by approximately 16%, double the overall revenue growth rate

BambooWorks

Aier

CHAOJU EYE CARE

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

C-MER MEDICAL

Looking for overseas growth, Aier Eye seeks Hong Kong listing

Aier's board of directors has approved the relevant proposal for listing in Hong Kong, which requires approval from the shareholders' meeting and regulatory authorities. The company's profit is expected to decline by 8.88% in 2025, but the net profit in the first quarter of 2023 rebounded to 1.181 billion yuan, a year-on-year increase of 12.46%. Overseas business has become a new highlight, with expected overseas revenue reaching 3.057 billion yuan in 2025, accounting for 13.68% of total revenue. This listing aims to broaden international financing channels, and management stated that this move is to address valuation pressure and seek new narratives in the capital market

Aier plans to go public in Hong Kong. Can overseas expansion support the new valuation of "eye king"?

09:49 AM EST - Kits Eyecare Ltd. : Is providing selected preliminary unaudited results for its first quarter ended March 31, 2026. Q1 Total Revenue Grew 23% Year-Over-Year to Approximately $57.4 Million Q1 Adjusted EBITDA Exceeded 6% of Revenue. Record Glasses Revenue of Approximately $10.8M, Grew 61% Year-Over-Year. Kits Eyecare Ltd. shares T.KITS are trading down $1.18 at $14.37.

Baystreet

Stocks in Play: Kits Eyecare Ltd.

ZHAOKE OPHTH Chairman Li Xiaoyi expects that in the second half of this year, multiple products will be approved one after another, including atropine sulfate eye drops for controlling myopia in adolescents, cyclosporine eye gel for treating dry eye syndrome, and bevacizumab intravitreal injection. In addition, the group plans to expand its international network to Latin America or South America

Tasty Money

ZHAOKE OPHTH (6622) expects three products to be approved successively this year

Zhaoke Ophthalmology is seeking approval from China's National Medical Products Administration for three ophthalmic medications, with Chairman Li Xiaoyi optimistic about receiving approval this year. The company plans to increase marketing expenses and personnel allocation, and aims to expand into overseas markets, targeting revenue generation by 2028. Zhaoke anticipates international sales to make up half of its total revenue, focusing on the Latin American market, especially Brazil. Additionally, the company is registering its products in Hong Kong and Macau for broader application in the Greater Bay Area.

CoinLive

Zhaoke Ophthalmology Anticipates Approval for Eye Medications in China This Year

ZHAOKE OPHTH (6622) expects that three core products will be approved successively, helping the company transform into a commercialized entity, with financial performance expected to improve and losses continuing to narrow. The company has nearly 1 billion RMB in cash, values cash flow, and plans to achieve cash flow self-sufficiency. Cyclosporine eye gel, low-concentration atropine, and TAB014 are expected to be approved within the next three months, with broad market prospects. The company will increase sales through public and private hospitals and e-commerce platforms, with the sales team expected to expand to over 100 people by the end of the year, and plans to achieve overseas revenue by 2028

Stheadline

ZHAOKE OPHTH expects that the three core products will be approved successively, driving sales growth and helping to narrow losses continuously

ZHAOKE OPHTH expects multiple product applications to be approved in the second half of the year, including cyclosporine eye gel and atropine sulfate eye drops. The company has established an internet hospital in Nansha, Guangzhou, and plans to expand to Latin America or South America. It is expected that overseas business will begin to generate revenue by 2028. The company's losses narrowed from RMB 237 million to RMB 209 million, and the vice president of finance anticipates that future product approvals will gradually reduce the losses

AASTOCKS

ZHAOKE OPHTH expects multiple product applications to be approved in the second half of the year, hoping to expand its international network to Latin America or South America this year

301103

159992

Zhaoke Ophthalmology Narrows Core Loss as Revenue Halves in 2025

HESH

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Zhaoke Ophthalmology Narrows Core Loss as Revenue Halves in 2025

Aier is considering an IPO in Hong Kong and is working with advisors to prepare for it, with the specific scale and timing still under discussion. The company has a market capitalization of approximately 96 billion RMB, and its stock price is close to a five-year low, having fallen about 26% in the past 12 months. Aier was founded in 2002, and its medical network covers Asia, Europe, and North America, with a total of 976 hospitals and clinics worldwide, including 807 in mainland China and 9 in Hong Kong

According to reports, Aier is considering listing in Hong Kong

ZHAOKE OPHTH-B(06622.HK)

Zhaoke Ophthalmology Shareholders Approve All Resolutions at 2026 AGM

Looking for overseas growth, Aier Eye seeks Hong Kong listing

Aier plans to go public in Hong Kong. Can overseas expansion support the new valuation of "eye king"?

Stocks in Play: Kits Eyecare Ltd.

ZHAOKE OPHTH (6622) expects three products to be approved successively this year

Zhaoke Ophthalmology Anticipates Approval for Eye Medications in China This Year

ZHAOKE OPHTH expects that the three core products will be approved successively, driving sales growth and helping to narrow losses continuously

ZHAOKE OPHTH expects multiple product applications to be approved in the second half of the year, hoping to expand its international network to Latin America or South America this year

Zhaoke Ophthalmology Narrows Core Loss as Revenue Halves in 2025

According to reports, Aier is considering listing in Hong Kong